文献速递静脉血栓栓塞慢性静脉疾病

日常实践中急性孤立性浅静脉血栓形成后迟发性静脉血栓栓塞事件的决定因素:INSIGHTS-SVT 研究 12 个月结果

Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2023-08-12

这项前瞻性观察研究纳入 872 例急性浅静脉血栓形成患者,随访 12 个月,主要疗效结局为症状性静脉血栓栓塞(VTE),发生率为 14.3%,其中复发或延伸性浅静脉血栓形成最常见(11.0%)。多变量模型显示,3 至 12 个月间发生事件的患者更可能具有较高 BMI(HR 1.06)、VTE 病史(HR 2.89)和严重全身性感染(HR 7.59)。作者认为,对于有危险因素的患者,可考虑超过 45 天的抗凝治疗。

要点

  • 12 个月时症状性 VTE 发生率为 14.3%,最常见为复发或延伸性浅静脉血栓形成(11.0%)。
  • LMWH 组主要疗效结局发生率最高(22.4%),磺达肝癸钠组最低(10.4%)。
  • 较高 BMI、VTE 病史和严重全身性感染与 3 至 12 个月间发生事件显著相关。

核心结论

  • 症状性 VTE 风险在 12 个月随访期间持续升高,对于有危险因素的患者,可考虑超过 45 天的抗凝治疗。

研究设计与样本

  • 前瞻性观察研究,纳入 872 例急性浅静脉血栓形成患者,由主管医师酌情治疗,随访 12 个月。

主要发现

  • 12 个月时 108 例患者(14.3%)达到主要疗效结局。
  • 最常见的 VTE 事件为复发或延伸性浅静脉血栓形成(11.0%),其次为症状性深静脉血栓形成(2.7%)、症状性肺栓塞(2.4%)、因 VTE 住院(1.8%)和死亡(1.1%)。
  • 临床相关出血事件发生于 2.1% 的患者,大出血发生于 0.3%。
  • 按药物分组,主要疗效结局发生率在 LMWH 组最高(22.4%),在磺达肝癸钠组最低(10.4%)。
  • 多变量模型中,3 至 12 个月间发生事件的患者更可能具有较高 BMI(HR 1.06;p = .002)、VTE 病史(HR 2.89;p = .002)和严重全身性感染(HR 7.59;p = .006)。

关键数值与推荐

  • 62.1% 的患者接受磺达肝癸钠(平均疗程 34.9 ± 15.7 天),25.0% 接受低分子量肝素(LMWH)(平均疗程 26.2 ± 23.2 天),6.2% 接受其他抗凝药,6.7% 未接受抗凝药。
  • 患者平均年龄 60.6 ± 14.5 岁,64.5% 为女性,80.1% 有慢性静脉疾病,41.9% 有 VTE 病史。

临床怎么用

  • 对于有危险因素(较高 BMI、VTE 病史、严重全身性感染)的患者,作者认为可考虑超过 45 天的抗凝治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long term incidence of symptomatic venous thromboembolism (VTE) and bleeding events in patients with superficial vein thrombosis (SVT) was investigated. METHODS: In this prospective, observational study, patients with acute SVT were treated at the discretion of the responsible physician. The primary efficacy outcome was symptomatic VTE including deep vein thrombosis (DVT), pulmonary embolism (PE), and recurrent or extending SVT. The primary safety outcome was clinically relevant bleeding, recorded at periodic clinic visits over a 12 month period. RESULTS: The mean age of 872 patients with 12 month follow up was 60.6 ± 14.5 years, 64.5% were female, 80.1% had chronic venous disease (defined as chronic venous insufficiency and or varicose veins), and 41.9% had a history of VTE. They were receiving fondaparinux in 62.1% (mean duration 34.9 ± 15.7 days), low molecular weight heparin (LMWH) in 25.0% (mean duration 26.2 ± 23.2 days), any other anticoagulants in 6.2%, and no anticoagulant in 6.7%. At 12 months, 108 patients (14.3%) achieved the primary efficacy outcome. The most common VTE event was recurrent or extending SVT in 11.0%, followed by symptomatic DVT in 2.7%, symptomatic PE in 2.4%, hospitalisation due to VTE in 1.8%, and death in 1.1%. Clinically relevant bleeding events occurred in 2.1% of patients, and major bleedings in 0.3%. By drug, the rate of the primary efficacy outcome was highest in the LMWH group (22.4%) and lowest in the fondaparinux group (10.4%). In a multivariable model, patients with events between three months and 12 months were significantly more likely to have higher BMI (hazard ratio [HR] 1.06; p = .002), history of VTE (HR 2.89; p = .002), and severe systemic infections (HR 7.59; p = .006). CONCLUSION: The risk of symptomatic VTE remained elevated over 12 months of follow up. Therefore, anticoagulation beyond 45 days may be considered in patients with risk factors. [ClinicalTrials.gov identifier: NCT02699151.].

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Rabe E, Hoffmann U, Schimke A, et al. Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study. Eur J Vasc Endovasc Surg. 2023. PMID: 37573936. doi:10.1016/j.ejvs.2023.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。